Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals

Simple item page
dc.contributor.authorPatil, Ruchaen_US
dc.contributor.authorShanbhag, Shardaen_US
dc.contributor.authorShankarkumar, Arunaen_US
dc.contributor.authorMadkaikar, Manishaen_US
dc.date.accessioned2023-08-19T04:52:11Z
dc.date.available2023-08-19T04:52:11Z
dc.date.issued2022-06
dc.description.abstractBackground & objectives: During the COVID-19 pandemic it was important to assess the antibody profile in individuals vaccinated with Covaxin (BBV152) and Covishield (ChAdOx1 nCoV-19) with both 28 and 84 days gaps between two doses, those infected with SARS-CoV-2 and post-COVID-19-infected individuals vaccinated with only one dose of either of the vaccines. The present study was aimed to assess these objectives. Methods: Fifty real time reverse transcription–polymerase chain reaction (qRT-PCR)-confirmed COVID-19-infected individuals, along with 90 COVID-19-naïve (BBV152 and ChAdOx1 nCov-19)–vaccinated individuals, were included in the study. Individuals who received a single dose of either vaccine with a confirmed past diagnosis of SARS-CoV-2 infection (n=15) were also included. Blood samples were collected strictly between the 4th and 5th wk after development of symptoms for SARS-CoV-2 infected individuals and after the first/second vaccination dose. Antibody profile assessment was done using whole-virus, spike-receptor binding domain (RBD) and nucleocapsid-specific ELISA kits along with neutralizing antibody kit. Results: There was an overall 97.7 per cent seropositivity rate in vaccinated individuals, and a strong correlation (R2=0.8, P<0.001) between neutralizing and spike-RBD antibodies. Among individuals who received two standard doses of ChAdOx1 nCoV-19 vaccine, the spike antibody levels developed were of higher titre with a longer prime boost interval than in those with shorter intervals (P<0.01). Individuals vaccinated with two doses as well as only one dose post-SARS-CoV-2 infection had high neutralizing and spike-specific antibodies. Interpretation & conclusions: High neutralizing and spike-specific antibodies were developed in individuals vaccinated only with one dose of either vaccine post-SARS-CoV-2 infection. With the main priority being vaccinating majority of the population in our country, single-dose administration to such individuals would be a sensible way to make the most of the limited supplies. Furthermore, neutralizing antibody levels observed in COVID-19-naïve vaccinees imply the need for booster vaccination.en_US
dc.identifier.affiliationsDepartment of Haemostasis and Thrombosis, ICMR-National Institute of Immunohaematology, Mumbai, Maharashtra, Indiaen_US
dc.identifier.citationPatil Rucha, Shanbhag Sharda, Shankarkumar Aruna, Madkaikar Manisha. Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals. Indian Journal of Medical Research. 2022 Jun; 155(5-6): 538–545en_US
dc.identifier.issn0971-5916
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/223626
dc.languageenen_US
dc.publisherWolters Kluwer – Medknowen_US
dc.relation.issuenumber5-6en_US
dc.relation.volume155en_US
dc.source.urihttps://doi.org/10.4103/ijmr.ijmr_3330_21en_US
dc.subjectBBV152en_US
dc.subjectChAdOx1 nCov-19en_US
dc.subjectneutralizing antibodyen_US
dc.subjectSARS-CoV-2 infectionen_US
dc.subjectspike-specific antibodyen_US
dc.subjectvaccinationen_US
dc.titleAntibody profile in post-vaccinated & SARS-CoV-2 infected individualsen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJMR2022v155n5-6p538.pdf
Size:
991.42 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Medical Research